Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL693257 | 0.97 | MAP2K1 (0.62) | MAP2K1MAP2K2 | |
| SCHEMBL695080 | 0.90 | MAP2K1 (0.52) | MAP2K1 | |
| SCHEMBL696643 | 0.89 | MAP2K1 (0.77) | MAP2K1MAP2K2 | |
| SCHEMBL694901 | 0.88 | MAP2K1 (0.65) | MAP2K1MAP2K2 | |
| SCHEMBL697300 | 0.88 | MAP2K1 (0.60) | MAP2K1 | |
| SCHEMBL695932 | 0.88 | MAP2K1 (0.60) | MAP2K1MAP2K2 | |
| SCHEMBL13613926 | 0.87 | MAP2K1 (0.80) | MAP2K1MAP2K2 | |
| SCHEMBL694135 | 0.87 | MAP2K1 (0.63) | MAP2K1 | |
| SCHEMBL13148423 | 0.87 | MAP2K1 (0.59) | MAP2K1MAP2K2 | |
| SCHEMBL716680 | 0.85 | MAP2K1 (0.65) | MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421612-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | Novartis AG (CH) | 2012-02-29 | — | — | EP | claimed |
| WO-2010121646-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | NOVARTIS AG (CH) | 2010-10-28 | — | — | WO | claimed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | claimed |
| EP-2421612-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | Novartis AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| WO-2011067348-A3 | MEK INHIBITOR SALTS AND SOLVATES THEREOF | NOVARTIS AG (CH) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011067348-A2 | MEK INHIBITOR SALTS AND SOLVATES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067348-A2 | MEK INHIBITOR SALTS AND SOLVATES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2010121646-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | NOVARTIS AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010121646-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | NOVARTIS AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NRAS, BRAF, MAP3K1 | MAP2K1 48/4885MAP2K2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.